Literature DB >> 10449511

Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility.

R A Howe1, M Wootton, P M Bennett, A P MacGowan, T R Walsh.   

Abstract

Vancomycin-sensitive, -intermediate, and -heterointermediate methicillin-resistant Staphylococcus aureus isolates were tested by using E-tests to explore the interaction of methicillin and vancomycin. For the vancomycin-intermediate and -heterointermediate strains both drugs showed antagonism at concentrations below their MICs but synergy at methicillin concentrations near the MIC. This property could be used to screen for heterointermediate S. aureus strains.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10449511      PMCID： PMC85462     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  A critical assessment of the agar dilution chequerboard technique for studying in-vitro antimicrobial interactions using a representative beta-lactam, aminoglycoside and fluoroquinolone.

Authors:  M Wootton; A J Hedges; K E Bowker; H A Holt; D S Reeves; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  1995-05       Impact factor: 5.790

2.  First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.

Authors:  M C Ploy; C Grélaud; C Martin; L de Lumley; F Denis
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

3.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

4.  Vancomycin-resistant Staphylococcus aureus.

Authors:  R A Howe; K E Bowker; T R Walsh; T G Feest; A P MacGowan
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

5.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

6.  Genetic control of population structure in heterogeneous strains of methicillin resistant Staphylococcus aureus.

Authors:  H de Lencastre; A M Figueiredo; A Tomasz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

7.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

8.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

Review 9.  Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

10.  Oxacillin-induced inhibition of protein and RNA synthesis in a tolerant Staphylococcus aureus isolate.

Authors:  P E Jablonski; M Mychajlonka
Journal:  J Bacteriol       Date:  1988-04       Impact factor: 3.490
View more
  7 in total

1.  Laboratory detection and investigation of reduced susceptibility to vancomycin in oxacillin-resistant Staphylococcus aureus.

Authors:  P D Midolo; T M Korman; D Kotsanas; P Russo; T G Kerr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

2.  In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Authors:  J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Majcherczyk; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

3.  Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.

Authors:  N Aritaka; H Hanaki; L Cui; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

4.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

5.  Nosocomial spread of a Staphylococcus capitis strain with heteroresistance to vancomycin in a neonatal intensive care unit.

Authors:  Wil C Van Der Zwet; Yvette J Debets-Ossenkopp; Erik Reinders; Maria Kapi; Paul H M Savelkoul; Ruurd M Van Elburg; Keiichi Hiramatsu; Christina M J E Vandenbroucke-Grauls
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

6.  Interactions between glycopeptides and beta-lactams against isogenic pairs of teicoplanin-susceptible and -resistant strains of Staphylococcus haemolyticus.

Authors:  Carla Vignaroli; Francesca Biavasco; Pietro E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Antibiotic sensitivity profile of bacterial pathogens in postoperative wound infections at a tertiary care hospital in Gujarat, India.

Authors:  Nutanbala N Goswami; Hiren R Trivedi; Alpesh Puri P Goswami; Tejas K Patel; C B Tripathi
Journal:  J Pharmacol Pharmacother       Date:  2011-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.